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ABSTRACT Glucagon solutions at pH 2.0 were subjected to mechanical agitation at 37C in the presence of a hydrophobic
surface to explore the details of aggregation and ﬁber formation. High-resolution intermittent-contact atomic force microscopy
performed in solution revealed the presence of aggregates after 0.5 h; however, longer agitation times resulted in the formation
of ﬁbrillated structures with varying levels of higher-order assembly. Height, periodicity, and amplitude measurements of these
structures allowed the identiﬁcation of four distinct ﬁber types. The most elementary ﬁber form, designated a ﬁlament, self-
associates in a speciﬁc wound fashion to produce protoﬁbrils composed of two ﬁlaments. Subsequent self-assembly of these
ﬁlaments and protoﬁbrils leads to two well-deﬁned ﬁbrillar motifs, termed Type I and Type II. Atomic force microscopy imaging of
pH 2.8 glucagon solutions not agitated or exposed to elevated temperature revealed the presence of amorphous aggregates
before the formation of ﬁbrillar structures similar to those seen at pH 2.0. Time-course solution Fourier transform infrared
spectroscopy and thioﬂavin T binding studies suggested that glucagon aggregation and ﬁbril formation were associated with the
development of b-sheet structure. The results of these studies are used to describe a possible mechanism for glucagon
aggregation and ﬁbrillation that is consistent with a hierarchical assembly model proposed for amyloid ﬁbril formation.
INTRODUCTION
The conversion of normally soluble proteins and peptides to
insoluble ﬁbrils or plaques referred to as amyloid is the sub-
ject of intense study, since the process has been associated
with more than 20 different diseases (1–5). On a molecular
basis, aggregation is driven by the existence of improperly
folded structures; however, details concerning the mecha-
nism of pathogenesis and the exact species involved are
currently the subject of debate (5). Perhaps one of the more
intriguing outcomes derived from research in this ﬁeld is the
understanding that nonnative self-assembly resulting in amy-
loid formation appears to be a generic property of polypep-
tide chains (2).
Nonnative self-assembly also presents one of the greatest
challenges to the development of protein and peptide bio-
pharmaceuticals (6,7). To maintain a therapeutic effect, the
integrity of higher-order structural elements speciﬁc to a given
molecule must be properly stabilized since disruptions to
native conformation have the potential to promote aggre-
gation, ﬁbrillation, gelation, and/or precipitation that can lead
to diminished activity or have serious toxicological, immu-
nological, or pharmacological consequences (6,8,9). Many
aspects related to formulation design of proteins and peptides
have the potential to perturb native structure, including pH,
ionic strength, concentration, or inclusion of excipients. In
addition, environmental factors such as agitation, shear, pres-
sure, interfaces, and temperature extremes encountered during
manufacturing operations, distribution, storage, and handling
of protein and peptide therapeutics can potentially compro-
mise properly folded conformation.
A variety of strategies are available to address the problem
of physical stabilization. For example, rational design to gen-
erate aggregation resistant analogs has proved to be feasible
in certain cases but requires that amino acid changes do not
impact activity or pharmacological properties (10). Addition
of various formulation additives, although largely an empir-
ical approach, has also been shown to be an effective way of
stabilizing native structure or inhibiting aggregation (6,7).
The more practical approach of minimizing or completely
avoiding exposure to conditions that disrupt structure and/
or promote aggregation is yet another option. However, to
successfully apply any of these strategies to achieve the nec-
essary physical stability for a protein or peptide biophar-
maceutical product, a detailed understanding of structural
properties and the factors that can potentially induce non-
native self-assembly is required.
Glucagon, a 29 amino acid peptide hormone playing an
important endogenous role in maintaining normal circulating
glucose levels, is commercially available as a pharmaceutical
preparation for the treatment of hypoglycemia and other
clinical applications (11). Due to limitations in both chemical
and physical stability of glucagon, the pharmaceutical pro-
duct is supplied as a lyophilized powder that must be used
immediately after reconstitution with its supplied aqueous
diluent (12). Of particular concern is the propensity of
glucagon to aggregate resulting in the formation of ﬁbrils and
gels; a process that can be stimulated by acidic pH, increased
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ionic strength, peptide concentration, agitation, and/or ele-
vated temperatures (12,13). Therefore, glucagon provides an
excellent relevant model for studying aggregation phenom-
ena and approaches for stabilization that may be generally
applicable to other protein and peptide biopharmaceuticals.
A recent report exploring the aggregation behavior of
glucagon and other peptides has shown that aging glucagon
solutions prepared at concentrations .2.5 mg/mL for 24 h
results in the production of cytotoxic amyloidogenic ﬁbrils
(14). However, solutions prepared at the clinical concentra-
tion of 1 mg/mL only formed ﬁbrils after aging for 30 days.
The stabilizing effect afforded by the conditions used in the
pharmaceutical preparation of glucagon is interesting and
provides additional opportunities to explore other factors ca-
pable of inducing aggregation. In this work, we examine the
mechanism of glucagon aggregation induced by agitation at
elevated temperature in the presence of a hydrophobic sur-
face. Structural features formed as a result of the physical
stress conditions are characterized by high-resolution atomic
force microscopy (AFM) and other biophysical techniques,
including thioﬂavin T (ThT) ﬂuorescence and solution-state
Fourier transform infrared (FTIR) spectroscopy.
METHODS
Materials
Recombinant glucagon (98% purity as measured by reversed-phase high-
performance liquid chromatography) was obtained from Eli Lilly and
Company (Indianapolis, IN) and used without further puriﬁcation. Sodium
hydroxide and hydrochloric acid were purchased from Sigma (St. Louis,
MO). ThT was purchased from MP Biomedicals (Aurora, OH). Ultrapure
water (resistivity .18 MV cm) supplied from a Millipore (Bedford, MA)
water puriﬁcation system was used to prepare all solutions. Solid 1/8-inch
diameter polytetraﬂuoroethylene (PTFE) beads used to provide a hydro-
phobic surface during mechanical agitation were obtained from Saint-Gobain
Performance Plastics (Poestenkill, NY). Muscovite mica, the substrate used
for AFM experiments, was purchased from SPI Supplies (West Chester,
PA). D2O, deuterated NaOH, and deuterated HCl were purchased from
Sigma-Aldrich (Oakville, Ontario,Canada).
Initiation of glucagon aggregation
Glucagon solutions were prepared at a concentration of 1 mg/ml by ﬁrst
dissolving the peptide in 14 mM NaOH and stirring for 1.5 h. This base
treatment step was conducted to remove any aggregated forms or ﬁbril/gel
seed nuclei that may be present in the glucagon used for the experiments
(12). Liquid chromatography/mass spectrometry analysis conducted on base-
treated glucagon solutions yielded molecular mass for the main peak and
two most prominent isoforms that were in excellent agreement with the
theoretical value for glucagon (3483 Da). We note that base treatment did not
appear to affect aggregation or ﬁber formation compared to untreated
solutions (data not shown). After the base treatment, the solutions were
adjusted to either pH 2.0 or pH 2.8 using 1 N HCl and passed through
Acrodisc (Pall, East Hills, NY) 0.2 mm low protein binding ﬁlters. Filtered
solutions of glucagon were ﬁlled into 2 ml glass vials (Fisher Scientiﬁc,
Hampton, NH) containing 10 PTFE beads to provide a hydrophobic surface
of consistent surface area. Sufﬁcient volume of the glucagon solution was
added to avoid an air headspace, and the vial openings were covered with a
0.01’’ PTFE liner and then sealed with a screw cap. Vials, PTFE beads and
PTFE liners were soaked in 0.1 N HCl for 2 days, rinsed with ultrapure water
until a constant pH was achieved, and thoroughly dried before use. To induce
aggregation, the ﬁlled vials were attached horizontally to a New Brunswick
Scientiﬁc model R2 reciprocal shaker (Edison, NJ), housed in a laboratory
oven, and agitated (100 rpm) at a controlled temperature of 37C for various
lengths of time.
AFM imaging
Intermittent-contact (tapping-mode) AFM imaging was performed in ﬂuid
using a Digital Instruments NanoScope III Multimode Atomic Force Micro-
scope (Veeco/Digital Instruments, Santa Barbara, CA) equipped with an
‘‘E’’ scanner (13.6 mm 3 13.6 mm maximum lateral scan area) using
100 mm oxide-sharpened silicon nitride V-shaped cantilevers with a nominal
spring constant of ;0.32 N/m installed in a combination contact/tapping
mode liquid ﬂow-cell sealed against a freshly cleaved mica substrate. All
images were collected as 512 3 512 pixel data sets at a typical scan rate of
1–2 Hz with a vertical tip oscillation frequency of 7–9 KHz. The AFM sam-
ples were prepared by direct deposition of an 8 ml aliquot of the glucagon
solutions onto freshly cleaved mica. All imaging was performed in ﬂuid
using protein-free solution. Fibril height, amplitude, and periodicity data
were obtained using the Nanoscope software section analysis tool and
quoted as the mean of 30–50 measurements 6 SD.
Infrared spectroscopy
Glucagon samples were prepared at a concentration of 1 mg/ml in 14 mM
deuterated NaOH with stirring for 1.5 h, followed by adjusting the pH to 2.0
or 2.8 using 1 N DCl. Solutions were then passed through Acrodisc (Pall)
0.2 mm low protein binding ﬁlters. The pH 2.0 solutions were ﬁlled into 2 ml
glass vials (Fisher Scientiﬁc) containing 10 PTFE beads and agitated for 2 h
as previously described. FTIR spectra were acquired with a Nicolet 6700
spectrometer equipped with a Thermo (Waltham, MA) Spectra-Tech Micro
Circle Cell Mount and a ZnSe rod, controlled by OMNIC software version
7.2. Single beam spectra were collected at a resolution of 2 cm1 from 4000
to 400 cm1. Spectra were processed using the OMNIC software package.
Final spectra represent averages of 500 scans after buffer subtraction,
followed by water vapor subtraction to remove excessive noise.
Thioﬂavin T-binding
Vials containing glucagon solutions were subjected to mechanical agitation
at 37C in the presence of a hydrophobic surface (PTFE beads, as described
earlier). At various times, vials were removed from the reciprocal shaker and
a 720 ml of sample was transferred to a 1.5 ml Eppendorf (Hamburg,
Germany) tube. An 80 ml aliquot of ThT solution prepared in water adjusted
to pH 2.0 was added to the glucagon sample to achieve a ﬁnal concentration
of 30 mM of the ﬂuorescent probe. Black, untreated microtiter plate wells
(Nalge Nunc International, Rochester, NY) were ﬁlled with 150 ml of the
glucagon containing ThT solutions. Fluorescence intensity was monitored
over time at ambient temperature using a SpectraMax GeminiEM Fluores-
cence Microtiter Plate Reader (Molecular Devices, Sunnyvale, CA) with
excitation and emission wavelengths of 440 nm and 480 nm, respectively.
Samples were measured at ambient, rather than elevated (37C), temper-
atures to arrest the aggregation process at speciﬁc time points.
RESULTS AND DISCUSSION
The pharmaceutical preparation of glucagon is a lyophilized
powder reconstituted to a concentration of 1 mg/ml with an
aqueous pH 2.0 diluent. Under these clinically relevant condi-
tions, glucagon is physically stable when used as instructed.
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In a recent study evaluating the aggregation propensity
of glucagon, 1 mg/ml solutions in 0.01 M HCl showed no
formation of amyloidogenic ﬁbers unless stored for longer
periods of time (14). These investigators also demonstrated
that other factors such as glucagon concentration and
temperature accelerated ﬁbrillation; however, speciﬁc mech-
anistic and molecular details concerning the nature of the
process were not provided. To address these questions
concerning glucagon aggregation and ﬁbrillation, we em-
ployed in situ intermittent-contact AFM, a scanning probe
technique that operates by measuring repulsive and attractive
forces between a vertically oscillating tip and the sample of
interest (15).
Whereas glucagon aggregation and ﬁbril formation is
notably slower at pH 2.0, the process can be accelerated
by mechanical agitation at elevated temperature enabling
investigation of the assembly process into higher-order
structures within a 24 h time period. To achieve rapid and
reproducible aggregation under controlled conditions, we
adapted the experimental system previously described to
study the nonnative assembly mechanism of insulin resulting
from exposure to a hydrophobic interface (16). After shaking
at 37C in the presence of a hydrophobic surface provided by
the addition of PTFE beads, glucagon solutions appeared
clear with no apparent change in viscosity detected by visual
examination, irrespective of the duration of agitation.
Inspection of pH 2.0 glucagon solutions by AFM after
agitation for 0.5 h revealed aggregates that were loosely
bound to the mica substrate (Fig. 1 a). In contrast, AFM
analysis of glucagon solutions agitated for 5 or 20 h re-
vealed ﬁbrillar structures (Fig. 1, b and c). Close inspection
of these structures revealed a well-deﬁned axial periodicity
(Fig. 1 b). These mature ﬁbers are primarily unbranched and
were up to several microns long. Morphologically, these
glucagon ﬁbers appeared very similar to the amyloid ﬁbrils
formed by a variety of other proteins including Ab-amyloid
(17), a-synuclein (18), and Ig light-chain protein SMA (19)
(SMA are the initials of the patient whose sequence was used
to clone the gene coding for the variable domain of lg light
chain). At longer agitation times, individual glucagon ﬁbers
appeared to wind together to yield higher-order structures,
and, in some cases, gave the appearance of branching, as
seen in the center of Fig. 1 b. The interaction of individual
ﬁbers, which may represent stages of the winding process,
can be seen in Fig. 1 c (arrows at left of image). At the region
noted by arrow 1, two ﬁbers lie parallel and are ‘‘in phase’’.
The ﬁbers are ‘‘out of phase’’ in the region indicated by
arrow 2, and appear to wind together to form a single feature
having periodicity noted by arrow 3. A perspective view of
these features is shown in Fig. 1 d.
Since feature width determinations are strongly dependent
on the size and shape of the AFM tip (20), height
FIGURE 1 (a) AFM height image of
a 1 mg/ml pH 2.0 glucagon solution
agitated at 37C in the presence of a
hydrophobic surface for 0.5 h. (b) After
continued agitation for 5 h, ﬁbers are
observed with periodicity along the
ﬁbril length. (c) Individual ﬁbers can
be resolved ‘‘in phase’’ and ‘‘out phase’’
(numbered white arrows; see text for
additional details) in the twisting pro-
cess and with varied thickness after
agitation for 20 h. (d) Perspective view
of panel (c). Vertical scale bar shows
height gradation with progression from
darker to lighter color corresponding to
taller features.
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measurements were used to characterize the different
glucagon ﬁber structures that formed during agitation.
Height measurements were performed at two positions along
a single ﬁber shown in Fig. 2 a. A ﬁber height of 2.4 6 0.2
nm was obtained from an analysis of multiple cross sections
perpendicular to the portion of the ﬁber labeled F. Further
along the same ﬁber, the height in the area labeled P is 4.76
0.3 nm, nearly twice the previous measurement. The region
that is 2.4 6 0.2 nm is the smallest height measurement
observed in the analysis of multiple AFM images of
glucagon solutions agitated longer than 0.5 h. We introduce
the term ﬁlament to describe ﬁbers having this height. In our
model, the region of the ﬁber that is nearly twice the original
ﬁlament height results from the interaction of a second
ﬁlament with the ﬁrst to yield, upon winding, a putatively
periodic structural feature. A similar winding of individual
ﬁlaments has been observed during amyloid formation of the
Ig light-chain protein SMA (19). These investigators used
the term protoﬁbril to describe the structure that results from
the assembly of two ﬁlaments, and we use this same nomen-
clature here to describe glucagon ﬁbers having a height of
;4.0 nm. Two additional distinct ﬁber morphologies are
observed in Fig. 2 b. The ﬁber indicated with the label TI has
a height of 9.0 6 0.6 nm, a value twice that of a protoﬁbril.
This measurement suggests the assembly of two protoﬁbrils
that have wound together to form the ﬁber. A structure with
this height was also identiﬁed in aggregated Ig light-chain
protein SMA and designated a Type I ﬁbril (19). Height
measurements of the ﬁber identiﬁed with the label TII in
Fig. 2 b revealed a value of 7.0 6 0.5 nm, suggesting the
assembly of three ﬁlaments wound together. Amyloid ﬁbers
of Ig light-chain protein SMA with this same morphology
have been termed Type II ﬁbrils (19). The highly ordered
Type I and Type II glucagon ﬁbrils as shown in Fig. 2 b were
typically observed with extended agitation times. It is
important to note that we cannot discount the possibility of
alternate assembly pathways giving rise to these same Type I
and Type II ﬁbril motifs. These include the association of
a ﬁlament with a protoﬁbril to yield a Type II ﬁbril, a
protoﬁbril with two ﬁlaments to form a Type I ﬁbril, or a
ﬁlament with a Type II ﬁbril resulting in a Type I ﬁbril (see
Fig. 7).
Amplitude and periodicity measurements on the various
glucagon ﬁber forms are made by proﬁling the structures
parallel to the long axis as shown in Fig. 3, a–c. Amplitudes
are measured by averaging height differences between each
peak and trough of the twist (red arrowheads). The ampli-
tude should be approximately equal to, or less than, the
height of individual ﬁlaments or protoﬁbrils forming the
wound structure. Amplitudes for the Type I and Type II
ﬁbrils shown in Fig. 3 are in good agreement with the heights
of individual protoﬁbrils and ﬁlaments comprising these
ﬁber types (Fig. 2). In contrast, the amplitude for the proto-
ﬁbril is approximately half the height of a single ﬁlament.
Periodicities are determined by averaging the peak to peak
distance of the twist (green arrowheads). These measure-
ments are indicative of how the individual ﬁlaments or
protoﬁbrils are twisted together to form the various ﬁber
types.
Height, amplitude, and periodicity measurements deter-
mined from AFM images of aggregated glucagon are in
close agreement with those obtained for amyloid ﬁbers of the
Ig light-chain protein SMA, despite substantial differences
in protein amino acid composition (Table 1) (19). Indeed,
FIGURE 2 (a) AFM height images corresponding to a ﬁlament (labeled
F) and protoﬁbril (labeled P) formed after 4 h of agitation at 37C in the
presence of a hydrophobic surface. (b) AFM height images corresponding
to a Type I (labeled TI) ﬁbril, Type II (labeled TII) ﬁbril, and protoﬁbril
(labeled P) formed after 5 h of agitation using the same conditions as
described in panel a. Height measurements on the ﬁbers in panel a were
obtained by section analysis yielding mean 6 SD values of 2.4 6 0.2 nm
(n ¼ 15) and 4.7 6 0.3 nm (n ¼ 8) for the ﬁlament and protoﬁbril,
respectively. Similar height analyses performed on the ﬁbers shown in panel
b yielded mean 6 SD values of 9.0 6 0.6 nm (n ¼ 14) and 7.0 6 0.5 nm
(n ¼ 16) for the Type I and Type II ﬁbrils, respectively.
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recent AFM studies have shown that amyloid ﬁbers obtained
from molecularly and functionally diverse proteins are
structurally similar (17,18,19,21,22). Although ﬁlament
formation may be inﬂuenced by amino acid sequence, for
instance through cysteine-mediated disuﬁde bond formation,
it has been recently suggested that long-range quaternary
structure interactions may facilitate amyloid ﬁber formation
(23). Regardless of how the ﬁlaments and/or ﬁbers form,
when structural comparisons are made between amyloid
ﬁbers, differences in the experimental conditions during
imaging must be taken into consideration. In Table 1, the
dimensions reported for ﬁbers produced in agitated glucagon
solutions are for hydrated structures, and it is not unexpected
that these measurements are marginally higher in some in-
stances than those of the dried Ig light-chain protein SMA
(19). We further note that Type II ﬁbril periodicity and
amplitude data for the Ig light-chain protein SMA ﬁbers were
not reported. Recent x-ray diffraction and electron micros-
copy data collected on a variety of amyloid forming proteins
have suggested that these ﬁber structures are water-ﬁlled
nanotubes (24). In the case of Ig light-chain protein SMA,
dehydration may cause the ﬁbers to collapse thereby inﬂu-
encing height, periodicity and amplitude measurements. It is
therefore important when comparing structural characteris-
tics and motifs between proteins, that the AFM imaging
conditions be self-consistent (i.e., either in air or similarly
hydrated).
The formation of mature glucagon ﬁbrils is consistent with
the general hierarchical assembly model for amyloid ﬁbers
proposed by Khurana et al. (18). However, the conditions
employed to generate glucagon ﬁbers made it difﬁcult to
capture early events in the assembly process before the
appearance of ﬁbrous structures. We have observed consid-
erable numbers of all ﬁber species (e.g., ﬁlaments, proto-
ﬁbrils, Type I, and Type II ﬁbrils) within 4–5 h after agitation
at 37C in the presence of a hydrophobic surface.Without any
FIGURE 3 By proﬁling a ﬁber parallel to its long
axis, amplitude and periodicity measurements were
obtained for (a, P) protoﬁbril, (b, TI) Type I ﬁbril, and
(c, TII) Type II ﬁbril. Mean 6 SD values are indicated
for amplitude (red arrowheads) and periodicity (green
arrowheads) measurements. The number of amplitude
and periodicity measurements determined for individ-
ual ﬁber types shown in panel a is 10 and 9; panel b is
12 and 12; and panel c is 14 and 17. Insets show
representations of ﬁber winding motifs.
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stimulus, glucagon solutions at pH 2.0 are quite stable and not
prone to aggregation or ﬁbril growth unless left for extended
periods of time (i.e., days tomonths). Thework ofOnoue et al.
conﬁrmed the pH 2.0 stabilization effect for glucagon (14). In
contrast, glucagon solutions prepared at pH 2.8 show a
marked increase in the rate of ﬁbril formation compared to pH
2.0, and physical stress imparted by agitation, elevated tem-
perature, or exposure to a hydrophobic surface is not nec-
essary to initiate the ﬁbrillation process. Fibers formed at pH
2.8 show similar morphology to those produced at pH 2.0
(data not shown). In an attempt to determine whether other
structural features occur before the formation of ﬁlaments
and/or protoﬁbrils, in situ AFM was employed to examine
1 mg/ml solutions of glucagon at pH 2.8.
AFM images obtained on the pH 2.8 glucagon solutions
immediately after preparation show structural features rep-
resentative of aggregated peptide randomly distributed over
the mica surface similar to those shown in Fig. 1 a, but the
aggregates are easily dislodged with scanning even under
low imaging forces. Upon aging of the solution (i.e., hours),
stable imaging of larger aggregates was achieved (Fig. 4). At
its maximum height, the structural feature observed is 4.4 nm
and is taller than a single ﬁlament formed after agitation at
elevated temperature in the presence of a hydrophobic sur-
face (Table 1). Similar clusters of amorphous particles were
observed in AFM images obtained on acidic solutions of
insulin exposed to elevated temperatures for 30–60 s, and it
was proposed that these entities were involved in the ﬁbril
assembly process (21). Loosely packed amorphous struc-
tures were also observed in AFM images obtained for Ig
light-chain protein SMA solutions prepared at higher pH
conditions than pH 2.0 where ﬁbrils are readily produced
(25). Both ﬁbrils and amorphous deposits form in Ig light-
chain protein SMA solutions after extended storage over
days. Such aggregate intermediates may retain higher water
content resulting in a more bulky appearance than mature
ﬁbrils since the release of water is expected to be charac-
teristic of ﬁbril formation (26–28).
Although we were unable to directly visualize the trans-
formation of the amorphous aggregates into ﬁbers for the pH
2.8 glucagon solutions, we contend that these structures
represent nascent preﬁbrillar precursors since the predomi-
nant features observed by AFM after 24 h of incubation are
ﬁlaments and higher-order ﬁber types. It should be noted that
our interpretations are based on imaging of surface-bound
species and that we cannot account for transformations that
occur in the bulk solution phase. Drying of samples before
AFM imaging, as was done in other work (21), can stop the
process at various times, enabling better resolution of the
apparent time-dependent relationship between the various
structural forms, but one needs to be concerned about the
possibility of inducing features as a result of water removal.
Care must also be exercised in the interpretation of our AFM
data collected under different aggregation/ﬁber forming con-
ditions. Other work has shown that the mechanism of ﬁbril
formation for the Ig light-chain protein SMA on surfaces was
signiﬁcantly different than in solution (29). In studies on
Ab1–40, solid-state
13C NMR was capable of resolving dif-
ferent ﬁbril morphologies depending on whether they were
formed under quiescent conditions or with agitation (30).
Within the resolution capabilities of the atomic force mi-
croscope, it does not appear that the different conditions used
to generate glucagon ﬁbrils in our work inﬂuences the mech-
anism of growth.
The conformational properties of proteins and peptides in
solution are important factors since partially folded states are
thought to be critical intermediates involved in aggregation
and subsequent ﬁbril formation (25,31,32,33,34). Glucagon
is a small, ﬂexible peptide that can adopt a variety of
conformational forms depending on solution conditions
FIGURE 4 AFM height image obtained for a 1 mg/ml pH 2.8 glucagon
solution aged 6 h at ambient temperature. The large amorphous aggregate
remained adsorbed to the mica over multiple scans. Vertical scale bar shows
height gradation with progression from darker to lighter color corresponding
to taller features.
TABLE 1 AFM measurements obtained for glucagon
aggregated structures
Structure Measurement Glucagon* Ig light-chainy
Filament Height 2.4 6 0.3 2.4 6 0.5
Protoﬁbril Height 3.9 6 0.7 nm 4.0 6 0.6 nm
Periodicity 67 6 8 nm 60 6 10 nm
Amplitude 1.1 6 0.3 nm 0.8 6 0.4 nm
Type I ﬁbril Height 9.0 6 0.8 nm 8.3 6 1.0 nm
Periodicity 93 6 7.2 nm 100 6 10 nm
Amplitude 4.1 6 0.7 nm 1.6 6 0.3 nm
Type II ﬁbril Height 6.8 6 0.7 nm 5.9 6 0.6 nm
Periodicity 115 6 25 nm –
Amplitude 3.1 6 1.2 nm –
*Values stated for glucagon ﬁbrils are mean 6 SD obtained from 30–50
height, periodicity, and amplitude measurements for each ﬁbril type from
three different images.
yResults from Ionescu-Zanetti et al. (19) shown for comparison.
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(35–38). The x-ray crystal structure indicates that the hor-
mone adopts a mainly a-helical structure, but this result is
likely inﬂuenced by the conditions used to prepare crystals
(39). Far-UV circular dichroism (CD) spectroscopy was used
to determine the conformation of glucagon at the pH con-
ditions used in our studies (data not shown). Whereas the CD
spectrum of a nonagitated glucagon solution at pH 2.0
revealed a predominantly random coil conformation with
some b-sheet character, we were unable to obtain CD spectra
on agitated glucagon solutions due to optical artifacts pre-
sumably resulting from the presence of aggregated forms in
the samples. We further note that CD spectroscopy revealed
no structural change for 1 mg/ml pH 2.0 glucagon solutions
that had been stored quiescently for 24 h. To further explore
solution state conformational properties of glucagon, time-
course FTIR spectroscopy was performed on 1.0 mg/mL
glucagon solutions adjusted to pH 2.0 and agitated at 37C
for 2 h in the presence of a hydrophobic surface. After this
treatment, we observed a spectral feature at;1620 cm1 that
developed over a 24-h period consistent with the transfor-
mation of glucagon to a b-sheet structure (Fig. 5). Glucagon
solutions prepared at pH 2.8 but not agitated nor exposed to
37C produced a similar spectral change over the same time
period (data not shown). These features are consistent with
those reported for air-dried glucagon ﬁbrils examined by at-
tenuated total reﬂection-FTIR spectroscopy (40).
To complement our CD and FTIR data and noting that
stacking of b-sheets is the predominant structure postulated
for ﬁbers, a dye binding assay using the extrinsic ﬂuo-
rescent probe ThT was applied to study the glucagon ﬁ-
brillation process. This approach is commonly used to
demonstrate the existence of b-sheets within the amyloid
ﬁbers (41,42). ThT is quenched in solution, but binding to
b-sheet structures provides the correct environment for in-
teractions that result in ﬂuorescence enhancement (43). A
characteristic ﬂuorescence emission response consists of
a lag period, followed by a growth phase that eventually
plateaus at a constant value (32). Increases in dye binding
and subsequent ﬂuorescence intensity responses have been
correlated with the growth of ﬁbrils (19,32). Fluorescence
emission was monitored in a series of glucagon solutions
adjusted to pH 2.0 and agitated for 2, 5, and 20 h at 37C in
the presence of a hydrophobic surface. Immediately after
agitation, ThT was added and ﬂuorescence intensities were
monitored over 24 h. Dye binding events are observed for
all samples (Fig. 6), with the longest agitation time
exhibiting the highest initial ﬂuorescence emission signal.
Note that the typical ﬂuorescence emission proﬁle is not
obtained, presumably because the lag period is over after 2 h
of agitation and the ﬁbrillation process is in full progress.
The increasing ﬂuorescence intensity observed over time
for samples agitated 2 and 5 h indicates that glucagon ﬁbrils
FIGURE 5 FTIR spectra for 1 mg/ml pH 2.0 glucagon acquired in
deuterated buffer solution for (a) t¼ 0 (solid line) and (b) t¼ 22.5 h (dashed
line) after agitation for 2 h at 37C in the presence of PTFE beads. Spectra
are plotted on a common absorbance scale and are vertically offset for
clarity. (**) Spectral band at ;1620 cm1.
FIGURE 6 ThT ﬂuorescence was monitored in a series of 1 mg/ml pH 2.0
glucagon samples agitated at 37C in the presence of a hydrophobic surface
for 2 h (¤), 5 h (:). or 20 h (n). After agitation at the indicated times, an
aliquot of each sample was removed and mixed with ThT. Fluorescence
emission was monitored at 480 nm. (Inset) ThT ﬂuorescence from control
sample not exposed to agitation or elevated temperature (d). Data represents
mean 6 SD for four replicates.
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continue to bind ThT during the time period after agitation.
In contrast, the sample agitated for 20 h remains relatively
constant throughout the observation period with an end-
point ﬂuorescence lower than that of samples agitated 2 and
5 h. This result argues that ThT cannot access the interior of
tightly wound glucagon ﬁbrils formed (i.e., after 20 h of
agitation) before the addition of ThT (Fig. 1 c) and further
suggests completion of the ﬁbrillation process. In the ab-
sence of agitation (i.e., t¼ 0 h on stock solution), we did not
observe any evidence of ﬂuorescence enhancement (Fig. 6,
inset). Although these ﬂuorescence and FTIR experiments
strongly suggest that ﬁber formation in glucagon is asso-
ciated with the development of b-sheet structure, it should
be noted that ThT ﬂuorescence is not a conclusive marker
of b-sheet structure, as has been reported recently (40), and
that the observed ThT ﬂuorescence is a consequence of a
number of factors, including ﬁbril density and ﬁlament
orientation.
Taken collectively, the results of our studies suggest a
potential mechanism for glucagon aggregation/ﬁbrillation.
Our ﬂuorescence dye binding and time-course FTIR spec-
troscopy data indicate that a conformational transition occurs
resulting in an increased level of b-sheet structure that may
initiate aggregation. Although structural changes and par-
tially folded intermediates have been implicated as critical
precursors in the aggregation/ﬁbrillation mechanisms of
other proteins (25,31–34,44), we cannot dismiss the possi-
bility that glucagon may be inherently poised to aggregate
without requiring a conformational change to stimulate
self-assembly, and that the observed increase in b-sheet
structure is a consequence of intermonomer interactions.
Inspection of the amino acid sequence reveals a contiguous
stretch of b-sheet favoring residues at positions 22–27 that
may predispose glucagon toward aggregation (45). Despite
this uncertainty in the initiation events, it appears that
aggregates (Figs. 1 a and 4) are produced early in the
ﬁbrillation process and these forms may serve as the nucleus
for ﬁlament growth. As the ﬁbrillation process progresses
over time, the ﬁlaments self-assemble and twist together to
produce protoﬁbrils, as well as Type I and Type II ﬁbrils
FIGURE 7 Glucagon aggregation and ﬁbrillation pro-
cess. Under appropriate conditions, glucagon self-associ-
ates, leading to the formation of soluble aggregates and
agglomerated forms that may be preﬁbrillar structures.
These putative preﬁbrillar precursors may grow into ﬁla-
ments that self-assemble to produce protoﬁbrils, Type I and
Type II ﬁbrils, by a variety of assembly mechanisms.
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(Fig. 7). Further work is required to elucidate the exact
mechanistic details of the ﬁbrillation pathway for glucagon.
Our AFM studies have enabled the characterization of
structural details involved in the glucagon aggregation/
ﬁbrillation process. Although a recent study on glucagon has
demonstrated that the peptide can aggregate to produce
cytotoxic amyloidogenic ﬁbrils, high-resolution information
on the nature of the ﬁbrous material was not provided (14).
We have determined the molecular properties of glucagon
ﬁbrils to be remarkably consistent with those demonstrated
for other amyloidogenic proteins and peptides (2–5), and
further suggest a putative mechanism for their formation that
is consistent with a general hierarchical model proposed for
amyloid assembly based on reported AFM studies (18).
Glucagon offers a distinct advantage over other proteins/
peptides for studying the mechanism of amyloid formation
because solution conditions under which aggregation/ﬁbril-
lation occurs are relevant to the pharmaceutical preparation
and its clinical use. A common practice in this ﬁeld is to
employ atypical solution conditions and grossly elevated
temperatures to instigate aggregation and ﬁbrillation. For
example, insulin ﬁbrils are formed in highly acidic pH so-
lutions exposed to temperatures of 60C or more for ex-
tended periods of time (21,46). Pharmaceutical preparations
of insulin typically do not experience these extreme condi-
tions, leaving some uncertainty about the practical relevance
of such studies. Furthermore, acidic pH and high temperature
are known to accelerate chemical degradation of insulin and
other proteins/peptides in general (47). The implications of
such complex mixtures of various native and chemically
degraded forms of insulin on the mechanism of aggregation
and ﬁbrillation remain poorly understood. Glucagon, how-
ever, allows for examination of its aggregation and ﬁbrilla-
tion mechanisms under pharmaceutically relevant acidic pH
solution conditions within a time period where chemical
degradation is less of an issue.
Stabilization of natively folded protein and peptide struc-
tures against conformational denaturation, aggregation, and
potential ﬁbrillation is a considerable challenge and gener-
ally hinders the development and commercialization of bio-
pharmaceutical products (6,7). These degradation pathways
must be prevented or adequately controlled because the
resulting end products can have diminished activity and/or
serious toxicological, immunological, or pharmacological
consequences (6,8,9). Current approaches used for stabili-
zation, however, are mostly empirical (6,7). A detailed
molecular understanding of degradation pathways involving
higher-order structural transitions, as demonstrated here for
glucagon, will ultimately enable more rational design of
physically stable biopharmaceutical formulations.
The common mechanistic features emerging for nonnative
protein/peptide assembly have additional important implica-
tions for amyloid deposition diseases. Despite signiﬁcant
diversity in amino acid sequences and three-dimensional
folding, a number of proteins and peptides have been shown
to produce highly similar ﬁbrillated structures (2,3,4,5,48).
Understanding details of the aggregation/ﬁbrillation mech-
anism at the molecular level is crucial to developing ap-
proaches for pharmaceutical treatment or possible prevention
of amyloid deposition diseases. Glucagon can also serve as
an ideal model system for such studies.
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